Drug-drug interaction between diltiazem and tacrolimus in relation to CYP3A5 genotype status in Chinese pediatric patients with nephrotic range proteinuria: a retrospective study

• Hoofdauteurs: Qiaoling Yang (Auteur), Yan Wang (Auteur), Xuebin Wang (Auteur), Ping Wang (Auteur), Boyu Tan (Auteur), Yijun Li (Auteur), Huajun Sun (Auteur), Wenyan Huang (Auteur), Hongxia Liu (Auteur)
• Formaat: Boek
• Gepubliceerd in: Frontiers Media S.A., 2024-09-01T00:00:00Z.
• Onderwerpen: article
• Online toegang: Connect to this object online.

BackgroundTacrolimus is widely used to treat pediatric nephrotic range proteinuria (NRP). Diltiazem, a CYP3A4/5 inhibitor, is often administered with tacrolimus, affecting its pharmacokinetic profile. The impact of this combination on tacrolimus exposure, particularly in CYP3A5*3 genetic polymorphis...